Market Analysis on Generic Medicine

International Journal of Collaborative Research on Internal Medicine & Public Health

ISSN - 1840-4529

Editor’s Note - (2021) Volume 13, Issue 4

Market Analysis on Generic Medicine

Vida Ebrahim*
*Correspondence: Vida Ebrahim, Director, Commercial Strategic Operations at Latham Bio Pharm Group, Iran,

Author info »


A large number of studies have focussed on the determinants of the entry of generics in the pharmaceuticals market. Most of them focus on the United States market. Much less evidence is found about heavily regulated pharmaceutical markets, such as the Portuguese market. This study uses data from Portugal, for the period 2000–2015. Based on a sample of 50 reimbursable outpatient drugs, that face potential entry of generics, two econometric models were estimated aiming to identify the determinants of entry and penetration of generics. The active substances included were chosen among those that represent the highest financial burden to the National Health System or are the most sold (in volume). To each of those active substances, the most sold pharmaceutical form, dosage, and package size was chosen. Our results suggest that market size is the main determinant of the generics entry. Concerning market penetration, our results show that it is determined by the number of marketed generics, as well as by price differences between brands and generics.

Graphical Abstract:

Frank Orlowski Director, Government & Commercial Strategic Operations at Latham BioPharm Group.As a Retired Executive, Frank worked for over 25 years at Pfizer in positions of responsibility in Finance, Strategy, & Operations. Frank lead the Supply Chain & Finance function across Asia, Middle East, South America & Eastern Europe developing business, operational & financial product localization strategies. He had direct financial control of over $2 Billion with a team of over 100 in-country operational colleagues across 35 Markets.

Publication of speakers:

1. One Billion USD FCPA Fine imposed by DOJ, but Goldman not admitting any wrongdoing.

2. A Human Perspective -- Global Business in the Post COVID-19 World and The New Norm.

3. The Human Factor of the Novel Coronavirus (COVID-19) and Corruption

Author Info

Vida Ebrahim*
Director, Commercial Strategic Operations at Latham Bio Pharm Group, Iran

Copyright:This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.